YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
91 hedge funds and large institutions have $330M invested in Y-mAbs Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 34 increasing their positions, 26 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
91
Holders Change
+3
Holders Change %
+3.41%
% of All Funds
1.54%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
13
Increased
34
Reduced
26
Closed
8
Calls
$2.59M
Puts
$6K
Net Calls
+$2.58M
Net Calls Change
-$97K
Top Buyers
| 1 |
Walleye Capital
New York
|
+$6.3M |
| 2 |
PA
Perceptive Advisors
New York
|
+$3.21M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.05M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$1.52M |
| 5 |
Millennium Management
New York
|
+$1.24M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$8.56M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$4.99M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.55M |
| 4 |
Morgan Stanley
New York
|
-$2.53M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$2.32M |
